Home › Opioid Overdose › NCT06288711
Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * \>18 years old * Maintained on a stable methadone or buprenorphine dose for \>1 month prior to the study * Meet current DSM-5 posttraumatic stress disorder criteria based on the Clinician Administered PTSD Scale for DSM-5 * Participants receiving psychotropic medications must be maintained on a stable dose for \>1 month prior to enrollment. Exclusion Criteria: * Current delusions or hallucinations, unstable bipolar disorder, imminent risk for suicide as assessed by the Mini International Neuropsychiatric Interview * Cognitive impairment as evidenced by scores \<22 on the Videoconference-based Mini Mental Status Examination (MMSE; Folstein, et al., 1975) * Enrolled in another ongoing evidence-based treatment for PTSD. * Pregnancy as verified by pregnancy test * No access to cellular service
About the study
Among individuals with opioid use disorder (OUD), posttraumatic stress disorder (PTSD) presents a significant clinical challenge. The prevalence of PTSD is substantially higher in individuals with OUD than in the general population, with nearly 90% reporting lifetime trauma exposure and 33% meeting diagnostic criteria for PTSD. The primary objective of this study is to evaluate the efficacy of a novel telemedicine-delivered prolonged exposure therapy protocol for improving PE attendance and reducing PTSD symptom severity in individuals with concurrent PTSD and OUD.
What is being tested
- Prolonged exposure therapy (behavioral)
- Financial incentives (behavioral)
- Treatment as usual (behavioral)
Sponsor: University of Vermont · Participants: 135 · Started: Jun 3, 2024
Contact the study team
- Kelly Peck, Ph.D. · Phone: 8026569610
Official record on ClinicalTrials.gov — NCT06288711
Locations in the U.S.
| Vermont | University of Vemont, Burlington |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.